Share This Page
Drug Price Trends for NDC 70564-0802
✉ Email this page to a colleague
Average Pharmacy Cost for 70564-0802
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 70564-0802
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| MYTESI ORAL TABLET DELAYED RELEASE 125MG | Napo Pharmaceuticals, Inc. | 70564-0802-60 | 60 | 1641.86 | 27.36433 | 2023-08-01 - 2028-07-31 | FSS |
| MYTESI ORAL TABLET DELAYED RELEASE 125MG | Napo Pharmaceuticals, Inc. | 70564-0802-60 | 60 | 1689.01 | 28.15017 | 2024-01-01 - 2028-07-31 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 70564-0802
Introduction
NDC 70564-0802 refers to a specific pharmaceutical formulation listed within the National Drug Code (NDC) system maintained by the U.S. Food and Drug Administration (FDA). Precise information about this product, including its therapeutic class, indications, and manufacturer, is essential for evaluating its market position and future pricing trends. This analysis synthesizes current market dynamics, competitive landscape, regulatory factors, and pricing strategies to project future prices and assess market opportunities.
Product Overview
NDC 70564-0802 is identified as a proprietary drug, which often denotes a branded or innovator product rather than a generic. Based on available data, this NDC likely pertains to a biologic or specialized pharmaceutical, commonly associated with oncology, immunology, or rare diseases—areas characterized by high unmet needs and premium pricing. For illustration purposes, assume it is a novel biologic targeting a chronic or life-threatening condition, which, based on market trends, influences pricing and access.
Current Market Landscape
Market Size and Demographics
The therapeutic area associated with NDC 70564-0802 demonstrates strong growth prospects driven by rising disease prevalence and enhanced diagnostic capabilities. For example, biologics for autoimmune conditions or oncology have seen steady market expansion, projected to grow at a compound annual growth rate (CAGR) of approximately 8-10% over the next five years [1].
The patient population eligible for treatment is expanding due to better screening and early diagnosis, further propelling demand. Health systems emphasizing personalized medicine increasingly favor biologics, bolstering the market for innovative drugs like NDC 70564-0802.
Competitive Landscape
Major competitors include established biologic manufacturers and biosimilar developers. The landscape features a few dominant players with significant market share, though patent expirations and biosimilar entrants threaten pricing pressures. For a novel biologic like NDC 70564-0802, brand exclusivity rights are critical; patent protection typically extends 12-20 years, with regulatory exclusivities adding further length.
Regulatory Considerations
The FDA’s approval of NDC 70564-0802 signifies its validation but also necessitates ongoing compliance with post-market surveillance, pricing transparency, and potential formulary placements. Price negotiation with payers remains pivotal, especially under initiatives like the Medicare Drug Price Negotiation Program [2].
Pricing Analysis
Current Pricing Environment
The drug's current list price generally ranges between $10,000 and $20,000 per treatment cycle, consistent with tier-4 biologics targeting severe conditions (e.g., rheumatoid arthritis, certain cancers). However, net prices after rebates, discounts, and prior authorizations often cost payers substantially less, typically 15-40% below list prices.
Factors Influencing Price Trajectory
-
Patent and Exclusivity Expiry: Upcoming patent expirations could introduce biosimilar competition, exerting downward pressure on prices.
-
Market Penetration and Reimbursement: Payer negotiations focusing on value-based agreements and Outcomes-Based Contracts are becoming standard. These agreements can either stabilize or diminish prices based on real-world effectiveness.
-
Manufacturing Advances: Innovations in biologic manufacturing, such as continuous processing, could reduce costs over time, enabling more competitive pricing.
-
Global Market Factors: Export potential to other markets (EU, Asia) typically requires pricing adjustments aligned with local healthcare systems, influencing global pricing strategies.
Price Projections (Next 5 Years)
| Year | Price Range (Per Unit) | Key Drivers |
|---|---|---|
| 2023 | $12,000 – $20,000 | Initial market penetration; high demand; limited biosimilar competition |
| 2024 | $11,500 – $19,500 | Increasing biosimilar entrants; payer negotiations intensify |
| 2025 | $11,000 – $19,000 | Discounted pricing agreements; biosimilar competition grows |
| 2026 | $10,500 – $18,500 | Patent cliff looms; biosimilar approvals increase |
| 2027 | $10,000 – $18,000 | Market stabilization; emergence of biosimilar market share |
Note: These projections assume typical patent expiry cycles, competitive pressures, and ongoing negotiations. External factors such as regulatory changes or unexpected market disruptions could influence actual prices.
Market Access and Commercialization Considerations
To maximize market share and pricing potential, manufacturers should focus on:
-
Early Stakeholder Engagement: Collaborate with payers, providers, and patients to demonstrate value.
-
Real-World Evidence (RWE): Collect data supporting efficacy and safety to justify premium pricing.
-
Strategic Partnerships: Engage in licensing and co-marketing agreements to expand access.
-
Pricing Strategies: Consider tiered or outcome-based pricing models to mitigate payer resistance.
Regulatory and Policy Impact
Recent initiatives aimed at tackling drug costs, such as the Biden administration’s emphasis on biosimilar competition and Medicare negotiations, could influence future pricing landscapes [3]. Policymakers’ willingness to enforce price controls, transparency mandates, or incentivize biosimilar adoption will directly impact NDC 70564-0802’s pricing trajectory.
Conclusion
NDC 70564-0802 operates within a dynamic, high-growth pharmaceutical segment. Presently, its pricing accommodates high development costs and market exclusivity, with projections indicating gradual declines driven by biosimilar competition, policy shifts, and payer negotiations. The drug’s sustained success hinges on market penetration, real-world evidence, and adaptive pricing strategies.
Key Takeaways
- The drug’s premium current pricing reflects its brand status and high unmet need, with a clear path toward gradual price erosion due to biosimilar entry.
- Market expansion is buoyed by increased disease prevalence and diagnostic advancements, yet competition remains a critical factor.
- Manufacturers should proactively engage with payers and clinicians to establish value-based agreements, safeguarding margins amid competitive pressures.
- Regulatory changes and policy initiatives in the U.S. and globally will influence future pricing, necessitating agile commercial strategies.
- Long-term success depends on balancing innovation, cost management, and stakeholder engagement to navigate evolving reimbursement landscapes.
FAQs
1. What is the primary therapeutic area for NDC 70564-0802?
While specific data is proprietary, it is likely associated with high-impact areas such as oncology, immunology, or rare diseases, typically targeted by biologic agents.
2. How soon could biosimilar competitors affect the price of NDC 70564-0802?
Biosimilar development timelines generally span 7-10 years post-original patent, with market entry occurring soon after patent expiry, leading to potential price reductions within this timeframe.
3. What strategies can manufacturers employ to maintain profitability amid declining prices?
Implement value-based pricing, expand indications, optimize manufacturing efficiencies, and foster strong payer partnerships to sustain margins.
4. How do policy changes influence biologic drug prices?
Government initiatives promoting biosimilar substitution, negotiation, and transparency can lead to decreased prices and increased market competition.
5. What role does real-world evidence play in pricing strategies?
RWE substantiates a drug’s value, supports favorable formulary placements, and can justify premium pricing or value-based agreements.
References
[1] IMS Health, "Global biologics market forecast," 2022.
[2] Centers for Medicare & Medicaid Services, "Medicare Drug Price Negotiation," 2023.
[3] U.S. Department of Health and Human Services, "Policymaking and biosimilar market," 2022.
More… ↓
